INBX
Inhibrx Biosciences, Inc. (NASDAQ)
Healthcare — Biotechnology
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Price History
Fundamentals
| Market Cap | $1.39B |
| P/E Ratio (TTM) | - |
| Forward P/E | -15.07 |
| EPS (TTM) | $-8.39 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -354.69% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $277.50 |
| Analysts | 2 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 68.8 |
| Beta | 3.32 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $155.29 |
| 52-Week Low | $15.82 |
| 50-Day Avg | $106.69 |
| 200-Day Avg | $77.72 |
| Avg Volume | 454.8K |
| Volume | 296.7K |
Performance Analysis
BULLISHINBX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:15 UTC
Back to Screener Export Report